Eli Lilly and Company $LLY Shares Sold by Handelsbanken Fonder AB

Key Points

• Handelsbanken Fonder AB reduced its Eli Lilly stake by 3.9% in the second quarter, selling 27,617 shares but retaining 680,927 shares valued at approximately $816.7 million. Institutional investors collectively own 82.53% of the stock.
• Eli Lilly reported a strong quarter, with revenue rising 47.7% year over year to $22.97 billion and earnings per share of $8.38, well above the $6.40 consensus estimate. The company issued fiscal 2026 EPS guidance of $35.50 to $36.50.
• The stock opened at $1,230, near its 12-month high, while analysts maintained a broadly positive outlook with a “Moderate Buy” consensus and an average price target of $1,292.18. An executive’s $5.95 million share sale occurred under a pre-arranged Rule 10b5-1 plan.

Handelsbanken Fonder AB cut its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 3.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 680,927 shares of the company's stock after selling 27,617 shares during the period. Eli Lilly and Company accounts for 2.3% of Handelsbanken Fonder AB's portfolio, making the stock its 8th largest holding. Handelsbanken Fonder AB owned 0.07% of Eli Lilly and Company worth $816,724,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the company. Spinnaker Investment Group LLC lifted its stake in Eli Lilly and Company by 65.4% in the 2nd quarter. Spinnaker Investment Group LLC now owns 473 shares of the company's stock valued at $568,000 after purchasing an additional 187 shares during the last quarter. A&I Financial Services LLC acquired a new position in Eli Lilly and Company during the second quarter worth approximately $239,000. Carolina Wealth Advisors LLC raised its stake in Eli Lilly and Company by 1.5% in the second quarter. Carolina Wealth Advisors LLC now owns 1,724 shares of the company's stock valued at $2,068,000 after buying an additional 25 shares during the period. Bay Colony Advisory Group Inc d b a Bay Colony Advisors raised its stake in Eli Lilly and Company by 1.7% in the second quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 5,083 shares of the company's stock valued at $6,097,000 after buying an additional 83 shares during the period. Finally, Community Financial Services Group LLC lifted its position in shares of Eli Lilly and Company by 16.4% in the second quarter. Community Financial Services Group LLC now owns 12,614 shares of the company's stock valued at $15,033,000 after buying an additional 1,774 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In related news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the sale, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.14% of the company's stock.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY opened at $1,230.00 on Tuesday. Eli Lilly and Company has a 12-month low of $625.90 and a 12-month high of $1,249.45. The company's 50 day moving average price is $1,162.38 and its two-hundred day moving average price is $1,048.95. The firm has a market cap of $1.16 trillion, a PE ratio of 41.28, a PEG ratio of 1.38 and a beta of 0.51. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating analysts' consensus estimates of $6.40 by $1.98. The company had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm's quarterly revenue was up 47.7% on a year-over-year basis. During the same period in the previous year, the business earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities research analysts predict that Eli Lilly and Company will post 36.77 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company's payout ratio is 23.22%.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The U.K. Medicines and Healthcare products Regulatory Agency approved Lilly’s Foundayo for weight loss and weight maintenance in certain adults with obesity or overweight-related health conditions. The authorization is the pill’s first European approval and gives Lilly access to a large potential market supported by its global commercial infrastructure. Eli Lilly’s GLP-1 Pill Secures First European Milestone
• Positive Sentiment: The approval also strengthens Lilly’s competitive position against Novo Nordisk in obesity drugs. Analysts and investors are increasingly focused on whether a convenient oral treatment can expand the GLP-1 market and increase patient adoption. Why Eli Lilly Topped the Market Today
• Positive Sentiment: Lilly’s latest quarterly performance remains a major support for the stock. Second-quarter revenue rose 47.7% year over year to approximately $23.0 billion, while adjusted EPS of $8.38 exceeded the $6.40 consensus estimate. Management set fiscal 2026 EPS guidance of $35.50 to $36.50, highlighting continued confidence in demand for its portfolio. Eli Lilly Posts Blowout Growth and Raises Its Outlook
• Neutral Sentiment: Investors are also weighing potential U.S. policies encouraging domestic pharmaceutical manufacturing. Lilly may be relatively well positioned if reshoring requirements favor companies with significant U.S. production capacity, although the policy details and costs remain uncertain. Eli Lilly vs. Novo Nordisk
• Neutral Sentiment: Sector rotation toward innovative healthcare companies, as investors seek alternatives to highly valued technology stocks, provided an additional supportive backdrop for Lilly. Jim Cramer Highlights Pharmaceutical Giants
• Negative Sentiment: Executive Vice President Anat Hakim sold 5,000 shares worth approximately $5.95 million under a pre-arranged Rule 10b5-1 trading plan. The transaction may attract attention, but its scheduled nature reduces its significance as a signal about Lilly’s outlook. SEC Form 4 Filing

Analyst Upgrades and Downgrades

Several brokerages have recently commented on LLY. Barclays lifted their target price on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an "overweight" rating in a research note on Monday, May 4th. Berenberg Bank lifted their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the stock a "hold" rating in a research report on Monday, June 22nd. Sanford C. Bernstein upped their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an "outperform" rating in a report on Tuesday, July 14th. JPMorgan Chase & Co. increased their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the company an "overweight" rating in a research report on Tuesday, July 7th. Finally, Leerink Partners raised their target price on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an "outperform" rating in a research note on Thursday, June 25th. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $1,292.18.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source